Altimmune, Inc. — Director's Dealing 2022

Oct 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-09-29

Reporting Person: Jorkasky Diane (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-29	Stock Options (option to buy)	$12.62	A	23500	Acquired	2032-09-29	Common Stock, par value $0.0001 (23500)	Direct

Footnotes

F1: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 29, 2022, subject to the reporting person's continued service through the applicable vesting date.